Amneal Pharmaceuticals to acquire the Baclofen franchise of Saol Therapeutics for $83m.

Amneal Pharmaceuticals, a fully-integrated essential medicines company, agreed to acquire the Baclofen franchise of Saol Therapeutics, a private specialty pharmaceutical company, for $83m. "For over 5 years, the Saol team has worked to reinvigorate the Lioresal® brand and develop new treatment options, like LYVISPAHTM, for patients struggling with spasticity. We are excited to see these products find their new home at Amneal along with many of our team members that have been critical to our success," David Penake, Saol Therapeutics CEO.